Greenland Mines Ltd

Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases, specifically cancer, cardiovascular, and neurodegenerative disorders, and is also involved in the development and mining of critical and precious minerals. The company operates two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that utilizes biologic therapies for cancer treatment, and a proprietary, patented gene therapy platform. This gene therapy platform introduces a therapeutic protein called "Klotho" into the body to treat neurodegenerative diseases. On September 12, 2022, Greenland Mines acquired five market-approved anti-cancer drugs authorized for sale in Germany. These Market Authorizations (MAs) cover four drugs used in the "FOLFOX" and "FOLFIRI" multi-drug regimens for metastatic colorectal and gastric cancer, and two drugs for metastatic lung cancer. These drugs are significant in treating various solid tumors in both childhood and adult cancers. Previously, the company acquired two off-patent biogeneric antibodies from Reliance Life Sciences. In March 2026, Greenland Mines completed the acquisition of Greenland Mines Corp., which expanded its operations into the development and mining of critical and precious minerals. The company's Common Stock and Warrants trade on the Nasdaq under the symbols "GRML" and "GRMLW" respectively. Its research pipeline focuses on developing essential medicines for chronic diseases, including a cell and gene therapy platform with proprietary technology programs (patents issued and pending) that includes a gene therapy program to produce the "Klotho" protein for neurodegenerative and other aging-related diseases (in-licensed pending patent applications from UAB).